Evidence map›Paper›PMID 36128202›Full record

ArticleMediterranean journal of rheumatology2022

The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study.

Farhad Salehzadeh, Farhad Pourfarzi, Sobhan Ataei

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 8 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 8 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. ESCMID COVID-19 living guidelines: drug treatment and clinical management.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Farhad SalehzadehPediatric Department, Bouali Children`s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Farhad PourfarziDepartment of Community Medicine, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Sobhan AtaeiPediatric Department, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Ardabil University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe acute respiratory syndrome due to COVID-19 infection has evolved into a global pandemic. This study has been designed to evaluate colchicine as an anti-inflammatory agent among COVID-19 patients regarding the disease course, duration of hospitalisation, and its morbidity and mortality rate. Methods: This prospective randomised and double-blind clinical trial study included 100 COVID-19 hospitalized patients with moderate symptoms from May 21 to June 20, 2020. They were randomised in a 1:1 allocation to placebo and colchicine groups plus recommended standard guideline and protocol of health system. Colchicine 1 mg has been taken daily for 6 days. All data including associated symptoms, co-existed disease and duration of hospitalisation evaluated initially, and then 2 weeks after discharge; moreover, their mortality and morbidity, re-admission, and deteriorations of symptoms were assessed during this period. Results: 59% were female with median age 56 years old. There was no significant difference between them in terms of age and sex. Two groups did not show significant difference about underlying diseases and various clinical and para clinical findings evaluation. However, there were significant difference in colchicine group regarding for shorter duration of fever (P<0.05) and hospitalisation (P<0.05). Although in colchicine group dyspnoea improved more rapidly than the placebo group, it was not meaningful. Conclusion: Colchicine can be effective in amelioration of systemic symptoms and duration of hospitalisation probably by inhibition of inflammatory biomarkers in COVID-19 patients.

Indexed as

colchicineCOVID-19

Identifiers

PMID36128202
PMCPMC9450200
OpenAlexW4294770139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.